Aurinia Pharmaceuticals (AUPH) Current Leases (2020 - 2026)

Aurinia Pharmaceuticals has reported Current Leases for 7 years, with the latest figure at $16.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 1494.5% year-over-year to $16.5 million; the trailing twelve-month figure through Mar 2026 stood at $16.5 million (up 1494.5% YoY), and the FY2025 full-year result was $1.1 million, up 4.0% from the prior year.
• Current Leases for Q1 2026 stood at $16.5 million, up from $1.1 million in the prior quarter.
• The five-year high for Current Leases was $16.5 million in Q1 2026, with the low at $918000.0 in Q3 2022.
• Historically, Current Leases has averaged $6.7 million across 5 years, with a median of $1.0 million in 2025.
• Annual changes were most pronounced in 2024 — Current Leases sank 92.98% — and 2025, when it surged 1503.87%.
• Aurinia Pharmaceuticals' Current Leases stood at $936000.0 in 2022, then surged by 1460.79% to $14.6 million in 2023, then sank by 92.98% to $1.0 million in 2024, then grew by 4.0% to $1.1 million in 2025, then surged by 1448.17% to $16.5 million in 2026.
• The last three Current Leases figures came in at $16.5 million (Q1 2026), $1.1 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.